Shilpa Medicare to make drug substance for Cadila's ZyCoV-D vaccine

Hyderabad’s Shilpa Medicare will make the drug substance (raw material) for Cadila Healthcare’s DNA plasmid vaccine ZyCoV-D at its Dharwad facility. ZyCoV-D is the world’s first approved DNA vaccine, and the first Covid-19 vaccine in India to be approved for use in adolescents 12 years and above.

The volumes, however, have not been disclosed at the moment. Under the agreement, Shilpa Biologicals, a subsidiary of Shilpa Medicare, will manufacture the drug substance of the vaccine, while Zydus will do the filling-packaging and distribution of the vaccine.

In a notification to the stock exchanges both the firms said that Shilpa Biologicals